Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report.

Abstract

Aripiprazole is an atypical neuroleptic with a unique mechanism of action. According to the package insert, the maximum recommended dose for aripiprazole is 30 mg/day. In clinical practice, off-label prescribing of medications, including the use of doses that exceed the manufacturer's recommendations, is not uncommon. Most premarketing studies are designed principally to demonstrate safety, efficacy, and tolerability and often exclude many patients who are treated after a drug has been released.To report a case with treatment-resistant schizoaffective disorder in which a patient tolerated and responded to high-dose aripiprazole; an objective is to discuss the use of aripiprazole dosages at higher than those recommended in the product's labelling.

• Authors: Omer Saatcioglu, Sevda Gumus, Kirkor Kamberyan, Medaim Yanik
• Journal: Psychopharmacology bulletin (Psychopharmacol Bull) Vol. 43 Issue 4 Pg. 70-2 ( 2010) ISSN: 0048-5764 [Print] United States
• PMID: 21240152 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antipsychotic Agents
• Piperazines
• Quinolones
• Aripiprazole

Topics

• Adult
• Antipsychotic Agents (administration & dosage)
• Aripiprazole
• Drug Labeling
• Drug Resistance
• Female
• Humans
• Off-Label Use
• Piperazines (administration & dosage)
• Psychotic Disorders (diagnosis, drug therapy, psychology)
• Quinolones (administration & dosage)
• Treatment Outcome